Department of Pharmacology & Neuroscience, University of North Texas Health Science Center, 3500 Camp Bowie Blvd, Fort Worth, TX, 76107-2699, USA.
Psychopharmacology (Berl). 2018 Mar;235(3):673-680. doi: 10.1007/s00213-017-4783-6. Epub 2017 Nov 14.
Novel synthetic cannabinoid compounds continue to appear in the market advertised as legal alternatives to marijuana and the older synthetic cannabinoid compounds which are now controlled substances. Most of these newer compounds have been found to act at CB1 receptors, so the purpose of this study was to study the abuse liability of these compounds.
Five of these compounds (BB-22, FUB-PB-22, 5F-AMB, NM2201, and MAB-CHMINACA) were tested for their ability to produce discriminative stimulus effects similar to Δ-tetrahydrocannabinol (Δ-THC) in rats. The ability of the CB1 receptor inverse agonist rimonabant to antagonize the discriminative stimulus effects of the five test compounds was also tested.
All five of the test compounds fully substituted for the discriminative stimulus effects of Δ-THC at some dose, although MAB-CHMINACA produced an inverted U-shaped dose effect. Rimonabant fully antagonized the Δ-THC-like discriminative stimulus effects of BB-22, 5F-AMB, NM2201, and MAB-CHMINACA but only reduced the effects of FUB-PB-22 to 40-50 % of Δ-THC-appropriate responding.
These findings suggest that all five of the test compounds produced Δ-THC-like effects and will likely have abuse liability similar to that of the controlled cannabinoid compounds.
新型合成大麻素化合物不断出现在市场上，被宣传为大麻和旧的合成大麻素化合物的合法替代品，这些旧的合成大麻素化合物现在已被列为管制物质。这些新化合物中的大多数已被发现作用于 CB1 受体，因此本研究旨在研究这些化合物的滥用倾向。
在大鼠中测试了这五种化合物（BB-22、FUB-PB-22、5F-AMB、NM2201 和 MAB-CHMINACA），以评估它们产生类似于 Δ-四氢大麻酚（Δ-THC）的辨别性刺激效应的能力。还测试了 CB1 受体反向激动剂利莫那班拮抗这五种测试化合物的辨别性刺激效应的能力。
所有这五种测试化合物都以某种剂量完全替代了 Δ-THC 的辨别性刺激效应，尽管 MAB-CHMINACA 产生了倒 U 形剂量效应。利莫那班完全拮抗了 BB-22、5F-AMB、NM2201 和 MAB-CHMINACA 的 Δ-THC 样辨别性刺激效应，但仅将 FUB-PB-22 的效应降低到 Δ-THC 适当反应的 40-50%。
这些发现表明，所有这五种测试化合物都产生了 Δ-THC 样的作用，并且可能具有类似于受管制大麻素化合物的滥用倾向。
